Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population (PARKA)

May 28, 2025 updated by: Université de Sherbrooke

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 4C4
        • Centre de recherche sur le vieillissement

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Alzheimer's or parkinson disease diagnostic
  • Stable medication associated with the disease
  • Able to consent
  • Presence of an accompanying person for the first and last visit.
  • Ability to read and talk in French

Exclusion Criteria:

  • MMSE < 20
  • MCT or coconut oil supplementation
  • Coconut allergy
  • Cannabis, THC or CBD consumption
  • Excessive alcohol consumption
  • Physical activity 3x/week
  • Presence of an metallic object in the body
  • Impossibility to lay in dorsal decubitus for 40 minutes
  • Cardiac disease
  • Any uncontrolled disease that could interfer with the project.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Parkinson disease
2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
Dietary supplement: Betaquik MCT supplement
50g/day divided in 3. Breakfast, lunch and dinner
Experimental: Alzheimer's disease
2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
Dietary supplement: Betaquik MCT supplement
50g/day divided in 3. Breakfast, lunch and dinner

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognition
Time Frame: 2 months, evaluation before and after intervention
Measure of cognition with CANTAB
2 months, evaluation before and after intervention
Ketones
Time Frame: 2 months, evaluation before and after intervention
Measurement of ketones concentrations
2 months, evaluation before and after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endocannabinoids
Time Frame: 2 months, evaluation before and after intervention
Endocannabinoids plasma concentration
2 months, evaluation before and after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université de Sherbrooke

Collaborators

Société des Produits Nestlé (SPN)

Investigators

  • Principal Investigator: Stephen Cunnane, Ph.D., Université de Sherbrooke

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Actual)

May 27, 2024

Study Completion (Actual)

May 27, 2024

Study Registration Dates

First Submitted

March 24, 2020

First Submitted That Met QC Criteria

March 24, 2020

First Posted (Actual)

March 26, 2020

Study Record Updates

Last Update Posted (Actual)

June 3, 2025

Last Update Submitted That Met QC Criteria

May 28, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-3436

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Betaquik MCT supplement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe